Alliance Pharma Has High Hopes For Recovering Chinese Market in 2023
Alliance Pharma is hopeful the end to COVID-19 movement restrictions in China will help to boost demand for its key consumer health brands Kelo-cote and Nizoral in 2023.
You may also be interested in...
A round-up of the latest appointments in Europe's consumer health industry: AESGP names Haleon's Workman as president; Alliance Pharma shareholders re-elect board; Food Supplements Europe re-elects Stada's Šímová as chair; and Venture Life announces departure of co-Founder and CCO Daly.
Alliance Pharma has delivered on its commitment to expand its US operations with a deal for Perrigo's ScarAway and Kelo-cote brands. For Perrigo, the divestment brings its acquisition of HRA Pharma a step closer by satisfying competition concerns.
Valbiotis and Nestlé Health Science plan to launch in 2024 a dietary supplement targeted at sufferers of prediabetes and type-2 diabetes following positive results from a recent study which showed the product's efficacy on key markers of glucose metabolism.